Johnson & Johnson President Brings Extensive McNeil Background To Post
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
You may also be interested in...
J&J asks MHRA for antifungal switch
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
J&J’s Lenehan Steps Down; Company Vision “Pretty Well Set”
Johnson & Johnson has no plans at the present time to fill its president position following the departure of former Consumer Pharmaceuticals & Professional Group Worldwide Chairman James Lenehan
J&J Nizoral AD 1% ketoconazole dandruff shampoo approved for OTC use Oct. 10.
J&J OTC NIZORAL AD DANDRUFF SHAMPOO GRANTED FDA APPROVAL for the control of flaking, scaling and itching. The agency cleared Johnson & Johnson's application to switch its ketoconazole 1% shampoo (NDA 20-310) on Oct. 10. The product will be marketed by J&J Consumer Products Group. J&J will continue to sell prescription Nizoral 2% shampoo but with a new indication: treatment of tinea versicolor, a topical fungal infection.